398 related articles for article (PubMed ID: 23021409)
1. Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.
Litim N; Labrie Y; Desjardins S; Ouellette G; Plourde K; Belleau P; ; Durocher F
Mol Oncol; 2013 Feb; 7(1):85-100. PubMed ID: 23021409
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
[TBL] [Abstract][Full Text] [Related]
4. The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.
Barroso E; Pita G; Arias JI; Menendez P; Zamora P; Blanco M; Benitez J; Ribas G
Breast Cancer Res Treat; 2009 Dec; 118(3):655-60. PubMed ID: 19536649
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
6. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.
Fierheller CT; Guitton-Sert L; Alenezi WM; Revil T; Oros KK; Gao Y; Bedard K; Arcand SL; Serruya C; Behl S; Meunier L; Fleury H; Fewings E; Subramanian DN; Nadaf J; Bruce JP; Bell R; Provencher D; Foulkes WD; El Haffaf Z; Mes-Masson AM; Majewski J; Pugh TJ; Tischkowitz M; James PA; Campbell IG; Greenwood CMT; Ragoussis J; Masson JY; Tonin PN
Genome Med; 2021 Dec; 13(1):186. PubMed ID: 34861889
[TBL] [Abstract][Full Text] [Related]
7. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
8. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
9. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
11. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
[TBL] [Abstract][Full Text] [Related]
12. Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.
Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Pichette R; Plante M; Durocher F;
Fam Cancer; 2007; 6(4):483-90. PubMed ID: 17636424
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk associated with BRCA1/2 variants in the Pakistani population.
Abbas S; Siddique A; Shahid N; Khan RT; Fatima W
Breast Cancer; 2019 May; 26(3):365-372. PubMed ID: 30430339
[TBL] [Abstract][Full Text] [Related]
14. New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein.
Fei P; Yin J; Wang W
Cell Cycle; 2005 Jan; 4(1):80-6. PubMed ID: 15611632
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC
Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497
[TBL] [Abstract][Full Text] [Related]
16. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.
Sawyer SL; Tian L; Kähkönen M; Schwartzentruber J; Kircher M; ; ; Majewski J; Dyment DA; Innes AM; Boycott KM; Moreau LA; Moilanen JS; Greenberg RA
Cancer Discov; 2015 Feb; 5(2):135-42. PubMed ID: 25472942
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
18. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
19. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway.
Xie J; Kim H; Moreau LA; Puhalla S; Garber J; Al Abo M; Takeda S; D'Andrea AD
J Clin Invest; 2015 Apr; 125(4):1523-32. PubMed ID: 25751062
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
